Results from new trials suggest that irinotecan improves response rates in patients with previously untreated colorectal cancer when added to conventional fluorouracil chemotherapy. The results, presented at the 35th Annual Meeting of the American Society of Clinical Oncology [Atlanta, US; May 1999], herald progress at last in the treatment of advanced colorectal cancer.